Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

Ardine M.J. Reedijk; Jan Willem W. Coebergh; Hester A. de Groot-Kruseman; Inge M. van der Sluis; Leontien C. Kremer; Henrike E. Karim-Kos; Rob Pieters

doi:10.1038/s41375-020-01024-0

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

Ardine M.J. Reedijk, Jan Willem W. Coebergh, Hester A. de Groot-Kruseman, Inge M. van der Sluis, Leontien C. Kremer, Henrike E. Karim-Kos^*, Rob Pieters

^*Corresponding author for this work

Public Health

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)

18 Downloads (Pure)

Abstract

We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87–147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10–14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15–17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990–94 to 91% in 2010–15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15–17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990–94 to 87% in 2010–15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10–14 years and T-cell ALL at age 15–17 years.

Original language	English
Pages (from-to)	1001-1011
Number of pages	11
Journal	Leukemia
Volume	35
Issue number	4
DOIs	https://doi.org/10.1038/s41375-020-01024-0
Publication status	Published - Apr 2021

Bibliographical note

Acknowledgements
The current work is funded by Stichting Kinderen Kankervrij (KiKa) [project number 207]. The funding source had no role in the study design, data collection, analyses and interpretation of the results, nor in writing of this manuscript. We thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. We thank Dr. Otto Visser (IKNL) for the extra data checks for the current study. We thank the laboratory personnel and the data managers from the Dutch Childhood Oncology Group (DCOG) for collecting the data for the DCOG registry. We recognise all paediatric oncologists who treated the patients and provided data in the DCLSG/DCOG collaboration.

Publisher Copyright: © 2020, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-020-01024-0

s41375-020-01024-0Final published version, 1.32 MBLicence: CC BY

Cite this

@article{20d929a67f314bb3bfe2cc5085d335ef,

title = "Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015",

abstract = "We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87–147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10–14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15–17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990–94 to 91% in 2010–15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15–17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990–94 to 87% in 2010–15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10–14 years and T-cell ALL at age 15–17 years.",

author = "Reedijk, {Ardine M.J.} and Coebergh, {Jan Willem W.} and {de Groot-Kruseman}, {Hester A.} and {van der Sluis}, {Inge M.} and Kremer, {Leontien C.} and Karim-Kos, {Henrike E.} and Rob Pieters",

note = "Acknowledgements The current work is funded by Stichting Kinderen Kankervrij (KiKa) [project number 207]. The funding source had no role in the study design, data collection, analyses and interpretation of the results, nor in writing of this manuscript. We thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. We thank Dr. Otto Visser (IKNL) for the extra data checks for the current study. We thank the laboratory personnel and the data managers from the Dutch Childhood Oncology Group (DCOG) for collecting the data for the DCOG registry. We recognise all paediatric oncologists who treated the patients and provided data in the DCLSG/DCOG collaboration. Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2021",

month = apr,

doi = "10.1038/s41375-020-01024-0",

language = "English",

volume = "35",

pages = "1001--1011",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

AU - Reedijk, Ardine M.J.

AU - Coebergh, Jan Willem W.

AU - de Groot-Kruseman, Hester A.

AU - van der Sluis, Inge M.

AU - Kremer, Leontien C.

AU - Karim-Kos, Henrike E.

AU - Pieters, Rob

N1 - Acknowledgements The current work is funded by Stichting Kinderen Kankervrij (KiKa) [project number 207]. The funding source had no role in the study design, data collection, analyses and interpretation of the results, nor in writing of this manuscript. We thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. We thank Dr. Otto Visser (IKNL) for the extra data checks for the current study. We thank the laboratory personnel and the data managers from the Dutch Childhood Oncology Group (DCOG) for collecting the data for the DCOG registry. We recognise all paediatric oncologists who treated the patients and provided data in the DCLSG/DCOG collaboration. Publisher Copyright: © 2020, The Author(s).

PY - 2021/4

Y1 - 2021/4

N2 - We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87–147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10–14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15–17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990–94 to 91% in 2010–15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15–17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990–94 to 87% in 2010–15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10–14 years and T-cell ALL at age 15–17 years.

AB - We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87–147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10–14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15–17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990–94 to 91% in 2010–15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15–17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990–94 to 87% in 2010–15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10–14 years and T-cell ALL at age 15–17 years.

UR - http://www.scopus.com/inward/record.url?scp=85089658886&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-01024-0

DO - 10.1038/s41375-020-01024-0

M3 - Article

C2 - 32820270

AN - SCOPUS:85089658886

SN - 0887-6924

VL - 35

SP - 1001

EP - 1011

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this